Antibacterial resistance worldwide: Causes, challenges and responses

Nature Medicine

Volumn 10, Issue 12S, 2004, Pages S122-S129

  Levy, Stuart B ^a   Bonnie, Marshall ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; KETOLIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; COMMENSALISM; DNA SYNTHESIS INHIBITION; DRUG EFFECT; ECOLOGY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RNA SYNTHESIS; TREATMENT FAILURE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MODELS, BIOLOGICAL; PUBLIC HEALTH;

ACINETOBACTER; ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); ENTEROBACTER; ENTEROBACTER CLOACAE; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 10944272743     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1145     Document Type: Review

References (103)

1. Levy, S. The Antibiotic Paradox: How Misuse of Antibiotics Destroys their Curative Powers (Perseus Cambridge, 2002).
2. Ash, C. (ed.) Trends in Microbiology vol.2, 341-422 (Elsevier, Cambridge, UK, 1994).
3. Levy, S.B. The challenge of antibiotic resistance. Sci. Am. 278, 46-53 (1998).
4. Levy, S.B. Microbial resistance to antibiotics. An evolving and persistent problem. Lancet 2, 83-88 (1982).
5. Barber, M. Infection by penicillin resistant Staphylococci. Lancet 2, 641-644 (1948).
6. Crofton, J. & Mitchison, D.A. Streptomycin resistance in pulmonary tuberculosis. Br. Med. J. 2, 1009-1015 (1948).
7. Watanabe, T. Infective heredity of multidrug resistance in bacteria. Bacteriol. Rev. 27, 87-115 (1963).
8. Olarte, J. Antibiotic resistance in Mexico. APUA Newsletter 1, 3ff (1983).
9. Levy, S.B. Antibiotic resistance: Consequences of inaction. Clin. Infect. Dis. 33 Suppl. 3, S124-S129 (2001).
10. Elwell, L., Roberts, M., Mayer, L. & Falkow, S. Plasmid-mediated p-lactamase production in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 11, 528-533 (1977).
11. De Graaff, J., Elwell, L.P. & Falkow, S. Molecular nature of two p-lactamase-speci- fying plasmids isolated from Haemophilus influenzae type b. J. Bacteriol. 126, 439-446 (1976).
12. Marshall, B., Roberts, M., Smith, A. & Levy, S.B. Homogeneity of transferable tetra- cycline resistance determinants in Hemophilus species. J. Infect. Dis. 149, 1028-1029 (1984).
13. van Klingeren, B., van Embden, J.D. & Dessens-Kroon, M. Plasmid-mediated chlo- ramphenicol resistance in Haemophilus influenzae. Antimicrob. Agents Chemother. 11, 383-387 (1977).
14. Bloom, B.R. & Murray, C.J.L. Tuberculosis: Commentary on a re-emergent killer. Science 257, 1055-1064 (1992).
15. Iseman, M.D. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. [erratum appears in N. Engl. J. Med. 329, 1435 (1993)] 329, 784-791 (1993).
16. Walsh, F.M. & Amyes, S.G.B. Microbiology and drug resistance mechanisms of fully resistant pathogens. Curr. Opin. Microbiol. 7, 439-444 (2004).
17. Weinstein, R.A. Controlling antimicrobial resistance in hospitals: Infection control and use of antibiotics. Emerg. Infect. Dis. 7, 188-192 (2001).
18. Anonymous. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2002 (2002).
19. Cosgrove, S.E. et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis. 36, 53-59 (2003).
20. Hiramatsu, K. Vancomycin resistance in staphylococci. Drug Resist. Updat. 1, 135-150 (1998).
21. Fridkin, S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know. Clin. Infect. Dis. 32, 108-115 (2001).
22. Weigel, L.M. et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302, 1569-1571 (2003).
23. Tenover, F.C. et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48, 275-280 (2004).
24. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37, 1563-1571 (1993).
25. Goossens, H. The epidemiology of vancomycin-resistant enterococci. Curr. Opin. Infect. Dis. 12, 537-541 (1999).
26. Jones, R.N., Ballow, C.H., Biedenbach, D.J., Deinhart, J.A. & Schentag, J.J. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28, 000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. 31, 437-451 (1998).
27. Meka, V.G. & Gold, H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39, 1010-1015 (2004).
28. Bush, K. New ß-lactamases in Gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32, 1085-1089 (2001).
29. Paterson, D.L. et al. International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum ß-lactamase production in nosocomial Infections. Ann. Intern. Med. 140, 26-32 (2004).
30. Bradford, P.A. Extended-spectrum ß-lactamases in the 21st century: Characterization, epidemiology and detection of this important resistance threat. Clin. Microbiol. Rev. 14, 933-951 (2001).
31. Nordmann, P. & Poirel, L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8, 321-331 (2002).
32. Livermore, D.M. & Woodford, N. Carbapenemases: A problem in waiting? Curr. Opin. Microbiol. 3, 489-495 (2000).
33. Wang, H., Dzink-Fox, J.L., Chen, M. & Levy, S.B. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: Role of acrR mutations. Antimicrob. Agents Chemother. 45, 1515-1521 (2001).
34. Zervos, M.J. et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin. Infect. Dis. 37, 1643-1648 (2003).
35. Karlowsky, J.A., Kelly, L.J., Thornsberry, C., Jones, M.E. & Sahm, D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 46, 2540-2545 (2002).
36. Schrag, S.J. et al. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob. Agents Chemother. 48, 3016-3023 (2004).
37. McCormick, A.W. et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat. Med. 9, 424-430 (2003).
38. Tanaka, M., Nakayama, H., Haraoka, M. & Saika, T. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. J. Clin. Microbiol. 38, 521-525 (2000).
39. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California. Morb. Mortal. Wkly. Rep. 51, 1041-1044 (2002).
40. Wang, S.A. et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001. Clin. Infect. Dis. 37, 849-852 (2003).
41. Vandenesch, F. et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg. Infect. Dis. 9, 978-984 (2003).
42. Herold, B. et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. J. Am. Med. Assoc. 279, 593-598 (1998).
43. Anonymous. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus- Minnesota and North Dakota, 1997-1999. J. Am. Med. Assoc. 282, 1123-1125 (1999).
44. Levy, S.B. Balancing the drug resistance equation. Trends Microbiol. 2, 341-342 (1994).
45. Levy, S.B. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J. Antimicrob. Chemother. 49, 25-30 (2002).
46. Mellon, M., Benbrook, C. & Benbrook, K.L. Hogging it: Estimates of antimicrobial abuse in livestock. (UCS Publications, Cambridge, UK, 2001).
47. Barza, M., S.L. Gorbach. The need to improve antimicrobial use in agriculture: Ecological and human health consequences. Clin Infect. Dis. 34, S71-S144 (2002).
48. US Congress. Office of Technology Assessment. Impacts of Antibiotic Resistant Bacteria (OTA-H-629, US Government Printing Office, Washington, DC, 1995).
49. Levy, S.B. & Miller, R.V. (eds.) Gene Transfer in the Environment (McGraw Hill, New York, 1989).
50. Schneiders, T., Amyes, S.G.B. & Levy, S.B. Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob. Agents Chemother. 47, 2831-2837 (2003).
51. Piddock, L.J. Mechanisms of fluoroquinolone resistance: An update 1994-1998. Drugs 2 Suppl. 2, 11-18 (1999).
52. Levy, S.B. Ecology of plasm ids and unique DNA sequences. in Engineered Organisms in the Environment: Scientific Issues (eds. Halvorson, H.O., Pramer, D. & Rogul, M.) 180-190 (ASM Press, Washington DC, 1985).
53. Datta, N. et al. R factors in Escherichia coli in faeces after oral chemotherapy in general practice. Lancet 1, 312-315 (1971).
54. Moller, J.K., Bak, A.L., Stenderup, A., Zachariae, H. & Afzelius, H. Changing patterns of plasmid-mediated drug resistance during tetracycline therapy. Antimicrob. Agents Chemother. 11, 388-391 (1977).
55. Levy, S.B., FitzGerald, G.B. & Macone, A.B. Changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. N. Engl. J. Med. 295, 583-588 (1976).
56. Summers, A.O. Generally overlooked fundamentals of bacterial genetics and ecology. Clin. Infect. Dis. 34 Suppl 3, S85-S92 (2002).
57. Sidhu, M.S., Heir, E., Leegaard, T., Wiger, K. & Holck, A. Frequency of disinfectant resistance genes and genetic linkage with ß-lactamase transposon Tn552 among clinical staphylococci. Antimicrob. Agents Chemother. 46, 2797-2803 (2002).
58. Barbosa, T.M. & Levy, S.B. The impact of antibiotic use on resistance development and persistence. Drug Resist. Updat. 3, 303-311 (2000).
59. Seppala, H. et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med. 337, 441-446 (1997).
60. Levy, S.B. Emergence of antibiotic-resistant bacteria in the intestinal flora of farm inhabitants. J. Infect. Dis. 137, 689-690 (1978).
61. Alekshun, M.N. & Levy, S.B. Regulation of chromosomally mediated multiple antibiotic resistance: The mar regulon. Antimicrob. Agents Chemother. 41, 2067-2075 (1997).
62. Levy, S.B. Antibiotic resistance: An ecological imbalance, in Antibiotic Resistance: Origins, Evolution, and Spread, 1-9 (J. Wiley, Chichester, UK, 1997).
63. Levy, S.B. Starting life resistance-free. N. Engl. J. Med. 323, 335-337 (1990).
64. Miller, Y.W. et al. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J. Antimicrob. Chemother. 38, 829-837 (1996).
65. Levy, S.B., Marshall, B., Schluederberg, S., Rowse, D. & Davis, J. High frequency of antimicrobial resistance in human fecal flora. Antimicrob. Agents Chemother. 32, 1801-1806 (1988).
66. Walson, J.L., Marshall, B., Pokhrel, B.M., Kafle, K.K. & Levy, S.B. Carriage of antibiotic-resistant fecal bacteria in Nepal reflects proximity to Kathmandu. J. Infect. Dis. 184, 1163-1169 (2001).
67. Kummerer, K. & Henninger, A. Promoting resistance by the emission of antibiotics from hospitals and households into effluent. Clin. Microbiol. Infect. 9, 1203-1214 (2003).
68. Rolland, R.M., Hausfater, G., Marshall, B. & Levy, S.B. Antibiotic-resistant bacteria in wild primates: Increased prevalence in baboons feeding on human refuse. Appl. Environ. Microbiol. 49, 791-794 (1985).
69. Corpet, D.E. Antibiotic resistance from food. N. Engl. J. Med. 318, 1206-1207 (1988).
70. Levy, S.B. Antibiotic resistant bacteria in food of man and animals, in Antimicrobials and Agriculture (ed. Woodbine, M.) 525-531 (Butterworths, London, 1984).
71. Marshall, B., Petrowski, D. & Levy, S.B. Inter- and intraspecies spread of Escherichia coli in a farm environment in the absence of antibiotic usage. Proc. Natl. Acad. Sci. USA 87, 6609-6613 (1990).
72. Vidaver, A. Uses of antimicrobials in plant agriculture. Clin. Infect. Dis. 34, S107-S110 (2002).
73. DeFlaun, M.F. & Levy, S.B. Genes and their varied hosts, in Gene Transfer in the Environment (eds. Levy, S.B. & Miller, R.V.) 1-32 (McGraw-Hill, New York, 1989).
74. Cohen, M.L., Wong, E.S. & Falkow, S. Common R-plasmids in Staphylococcus aureus and Staphylococcus epidermidis during a nosocomial Staphylococcus aureus outbreak. Antimicrob. Agents Chemother. 21, 210-215 (1982).
75. Pearman, J.W. & Grubb, W.B. Preventing the importation and establishment of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in Western Australia. APUA Newsletter 11, 1-2 (1993).
76. Turnidge, J., Lawson, P., Munro, R. & Benn, R. A national survey of antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals. Med. J. Aust. 150, 69-72 (1989).
77. Cooper, B.S. et al. Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): Systematic review of the literature. Br. Med. J. 329, 533 (2004).
78. Livermore, D. Can better prescribing turn the tide of resistance? Nat. Rev. Microbiol. 2, 73-78 (2004).
79. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm. Rep. 42, 1-8 (1993).
80. Alekshun, M.S.B.L. Targeting virulence to prevent infection: To kill or not to kill? Drug Discovery Today: Therapeutic Strategies (in the press) (2004).
81. Projan, S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003).
82. Simon, L., Gauvin, F., Amre, D.K. & Saint-Lous, P. & Lacroix, J. Serum procalci- tonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis. Clin. Infect. Dis. 39, 206-217 (2004).
83. Markou, N. et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care 7, R78-R83 (2003).
84. Bifani, P.J. et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. J. Am. Med. Assoc. 275, 452-457 (1996).
85. Soares, S., Kristinsson, K.G., Musser, J.M. & Tomasz, A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J. Infect. Dis. 168, 158-163 (1993).
86. Manges, A.R. et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N. Engl. J. Med. 345, 1007-1013 (2001).
87. WHO. Global Strategy for Containment of Antimicrobial Resistance (WHO, Geneva, 2001).
88. Holmberg, S.D., Solomon, S.L. & Blake, P.A. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9, 1065-1078 (1987).
89. Rubin, R.J. et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. 5, 9-17 (1999).
90. Phelps, C.E. Bug/drug resistance. Sometimes less is more. Med. Care 27, 194-203 (1989).
91. Hall, R.M. et al. Mobile gene cassettes and integrons in evolution. Ann. NY Acad. Sci. 870, 68-80 (1999).
92. Nandi, S., Maurer, J.J., Hofacre, C. & Summers, A.O. Gram-positive bacteria are a major reservoir of Class 1 antibiotic resistance integrons in poultry litter. Proc. Natl. Acad. Sci. USA 101, 7118-7122 (2004).
93. Clewell, D.B. & Gawron-Burke, C. Conjugative transposons and the dissemination of antibiotic resistance in streptococci. Annu. Rev. Microbiol. 40, 635-659 (1986).
94. Roberts, M.C. Tetracycline resistance determinants: Mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol. Rev. 19, 1-24 (1996).
95. Dowson, C.G., Coffey, T.J. & Spratt, B.G. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to p-lactam antibiotics. Trends Microbiol. 2, 361-366 (1994).
96. Spratt, B.G. Resistance to antibiotics mediated by target alterations. Science264, 388-393 (1994).
97. Balsalobre, L., Ferrandiz, M.J., Linares, J., Tubau, F. & de la Campa, A.G. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47, 2072-2081 (2003).
98. Levy, S.B. Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother. 36, 695-703 (1992).
99. Nikaido, H. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178, 5853-5859 (1996).
100. Levy, S.B. et al. Nomenclature for new tetracycline resistance determinants. Antimicrob. Agents Chemother. 43, 1523-1524 (1999).
101. McMurry, L.M. & Levy, S.B. Tetracycline resistance in gram-positive bacteria, in Gram-Positive Pathogens (ASM Press, Washington DC, 2000).
102. Martinez-Martinez, L., Pascual, A. & Jacoby, G.A. Quinolone resistance from a transferable plasmid. Lancet 351, 797-799 (1998).
103. Wang, M., Sahm, D.F., Jacoby, G.A. & Hooper, D.C. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob. Agents Chemother. 48, 1295-1299 (2004).